68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)

Peking Union Medical College Hospital

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05499936

Enrollment

Registered

2022-08-12

Start date

2021-10-01

Completion date

2022-12-31

Last updated

2022-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

68Ga-FAPI PET/CT, Metastatic Adenoid Cystic Carcinoma

Keywords

68Ga-FAPI, PET/CT, Adenoid Cystic Carcinoma

Brief summary

This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma（ACC）

Detailed description

68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has been widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma (ACC) is a rare epithelial malignant tumor, which usually originates from salivary glands. Its typical characteristics are long clinical course and high rate of distant metastasis. The purpose of this study was to investigate the clinical value of 68Ga Fapi pet/ct in metastatic adenoid cystic carcinoma.

Interventions

DRUG68Ga-FAPI

68Ga-FAPI were injected into the patients before the PET/CT scans

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* patients with ACC suspected metastatic tumor,and being able to provide basic information and sign the written informed consent form

Exclusion criteria

* claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study

Design outcomes

Primary

Measure	Time frame	Description
Standardized uptake value of 68Ga-FAPI in ACC	1 year	The maximum and mean standard uptake values (SUVmax and SUVmean) were measured in the background of lesion, liver, muscle and mediastinal blood pool, respectively.

Secondary

Measure	Time frame	Description
lesions detected by 68Ga-FAPI PET/CT	1 year	The number of target lesions in each organ system was calculated by 68Ga-FAPI PET/CT

Other

Measure	Time frame	Description
compared with 18F-FDG PET/CT or other imaging like CT and MRI	1 year	The number of lesions detected by 68Ga-FAPI PET/CT was compared with 18F-FDG PET/CT or other imaging like CT and MRI

Countries

China

Contacts

Primary ContactRongxi Wang

pumch_jacobwong@163.com+8619800370331

Backup ContactZhaohui Zhu

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026